5. Progressive supranuclear palsy Clinical trials / Disease details
Clinical trials : 89 / Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04786158 (ClinicalTrials.gov) | December 1, 2018 | 3/3/2021 | Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) | Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) | Progressive Supranuclear Palsy;Corticobasal Degeneration | Drug: Apomorphine | Fondation Ophtalmologique Adolphe de Rothschild | NULL | Completed | 18 Years | N/A | All | 7 | France |